Skip to main content
. Author manuscript; available in PMC: 2021 Jul 16.
Published in final edited form as: Clin Cancer Res. 2020 Jan 29;26(10):2318–2326. doi: 10.1158/1078-0432.CCR-19-3624

Figure 2:

Figure 2:

Progression-free and overall survival curves for each of the 4 arms and combined according to radiation dosage. Durva, durvalumab; Treme, tremelimumab; 8Gy × 1, 8Gy in one fraction; 5Gy × 5, 25Gy in 5 fractions.